MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ignyta Company Profile (NASDAQ:RXDX)

Consensus Ratings for Ignyta (NASDAQ:RXDX) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.67 (274.60% upside)

Analysts' Ratings History for Ignyta (NASDAQ:RXDX)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016JPMorgan Chase & Co.Initiated CoverageOverweight$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Cantor FitzgeraldReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Piper JaffrayReiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Credit SuisseLower Price TargetOutperform$19.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Ignyta (NASDAQ:RXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.26)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ignyta (NASDAQ:RXDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.63)($0.50)($0.57)
Q2 20162($0.67)($0.57)($0.62)
Q3 20162($0.64)($0.63)($0.64)
Q4 20162($0.73)($0.71)($0.72)
(Data provided by Zacks Investment Research)
Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ignyta (NASDAQ:RXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ignyta (NASDAQ:RXDX)
DateHeadline
06/29/16 06:06 PMWere Analysts Bearish Ignyta Inc (NASDAQ:RXDX) This Week? - Engelwood Daily
06/28/16 11:01 AMCovering the Bases on Ignyta, Inc. (NASDAQ:RXDX): Where is the Stock Going? - Press Telegraph
06/27/16 06:09 PMNext Weeks Broker Price Targets For Ignyta, Inc. (RXDX) - Fiscal Standard
06/25/16 09:56 AMIgnyta Gets A Bullish Initiation From JPMorgan
06/25/16 09:56 AMJP Morgan recorded (NASDAQ:RXDX) Ignyta Inc, increasing its stock price target to $15 earlier today
06/24/16 06:19 PMCaesars Entertainment Corporation (NASDAQ:CZR) went up 3.46%: Ignyta, Inc. (NASDAQ:RXDX), ORBCOMM, Inc ... - KC Register
06/23/16 08:54 AMIgnyta, Inc. (NasdaqCM:RXDX) Stock Momentum Hits EXTREME Weakness - CML News
06/23/16 06:19 AMCoverage initiated on Ignyta by JP Morgan -
06/20/16 07:47 AMThis Weeks Broker Views For Ignyta, Inc. (RXDX) - Fiscal Standard
06/17/16 02:52 PMIgnyta's Entrectinib Data May Come By Year's End; Cantor Keeps Buy Rating, But Stock Slips 4% - Cantor analyst Mara Goldstein likes Ignyta Inc (NASDAQ: RXDX) shares for the opportunity provided by Entrectinib, which has multiple indications. As a result, she is confident that the drug could generate a bigger market than expected. The brokerage reiterated its rating of Buy and kept $18.00 as his price object on the shares of the company. The analyst expects final data for Ignyta's Drug study might come before the end of the current year. However, the brokerage pointed out that the regulator's "Pediatric Oncology Subcommittee will discuss investigator interest in exploring potential pediatric development plans for five drug candidates, including Entrectinib, on ...Full story available on Benzinga.com
06/15/16 03:02 PMIGNYTA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi -
06/08/16 06:46 PMIGNYTA INC. (NASDAQ:RXDX) Financial Condition Compared to S&P 500 - CML News
06/06/16 10:05 AMIgnyta (RXDX) Announces Encouraging Interim RXDX-105 Phase 1 Data
06/05/16 08:00 AMIgnyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016 - [Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that interim results from the Phase 1 clinical trial of RXDX-105, the company’s orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF, were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology in Chicago .
06/04/16 09:12 AMInvestor's Healthcare Focused Stocks: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) , Ignyta, Inc. (NASDAQ:RXDX) - Is stories
06/02/16 06:42 PMIgnyta Inc (NASDAQ:RXDX)'s Company Shares Decreased 5.99% After Low Volatility - HNN - Ignyta Inc (NASDAQ:RXDX)'s Company Shares Decreased 5.99% After Low VolatilityHNNThe shares of Ignyta Inc (NASDAQ:RXDX) decreased by 5.99% in the last 20 days and lost 2.17% in the past 5 trading sessions. Ignyta Inc (NASDAQ:RXDX) shares opened at $6.75 in the last session and had intraday high of $6.88 and low of $6.55 for a ...Top Stock in Session: Ignyta, Inc. (NASDAQ:RXDX)The Postall 2 news articles »
06/02/16 06:42 PMIgnyta Inc (RXDX) Could Make You Big Time Money - Smarter Analyst - Smarter AnalystIgnyta Inc (RXDX) Could Make You Big Time MoneySmarter AnalystHaving done significant research and reviewing my AACR meeting notes I believe Ignyta (NASDAQ:RXDX) fits my model and is a huge steal at current levels. The personalized medicine company has a best-in-class cancer drug Entrectinib entering a pivotal ...
06/02/16 12:03 PMIgnyta, Inc. :RXDX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
05/30/16 10:15 PMIgnyta Inc (RXDX) Stock Rating Reaffirmed by Piper Jaffray - Let Me Know About This - Ignyta Inc (RXDX) Stock Rating Reaffirmed by Piper JaffrayLet Me Know About ThisIgnyta logo Ignyta Inc (NASDAQ:RXDX)'s stock had its “buy” rating reaffirmed by analysts at Piper Jaffray in a research note issued to investors on Sunday. They currently have a $32.00 price objective on the biopharmaceutical company's stock. Piper ...Ignyta, Inc. (RXDX) Broker Price Targets For The Coming WeekShare Trading NewsIgnyta Delaware (NASDAQ:RXDX) Shorted Shares Decreased By 37.35%Franklin Independentall 3 news articles »
05/28/16 07:02 PMArmistice Capital LLC Increased Ignyta INC (NASDAQ:RXDX) by $4.42 Million as Shares Declined - CCH Daily News - Armistice Capital LLC Increased Ignyta INC (NASDAQ:RXDX) by $4.42 Million as Shares DeclinedCCH Daily NewsArmistice Capital Llc increased its stake in Ignyta Inc (NASDAQ:RXDX) by 77.31% based on its latest 2016Q1 regulatory filing with the SEC. Armistice Capital Llc bought 736,000 shares as the company's stock declined 45.71% while stock markets rallied.and more »
05/26/16 03:00 PMIgnyta to Present at 2016 Jefferies Healthcare Conference - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, announced today that Jonathan Lim., M.D., its Chairman and Chief Executive Officer, will make a presentation at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 11:30 a.m.
05/25/16 07:00 PMInsiders Are Gradually Buying Ignyta, Inc. (NASDAQ:RXDX) - Wall Street Hints and News - Insiders Are Gradually Buying Ignyta, Inc. (NASDAQ:RXDX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Ignyta, Inc. (NASDAQ:RXDX) have increased their position in the stock by 1.77% over the past 6 months. Insiders now own 9.30% of total outstanding shares. There are both legal and illegal types of ...and more »
05/25/16 07:00 PMLatest Analyst Ratings For Ignyta, Inc. (RXDX) - Share Trading News - Latest Analyst Ratings For Ignyta, Inc. (RXDX)Share Trading NewsIgnyta, Inc. has a 50 day moving average of 7.17 and a 200 day moving average of 9.31. The stock's market capitalization is 287.35M, it has a 52-week low of 5.07 and a 52-week high of 19.40. The share price of the company (RXDX) was unchanged +0.00%, ...Were Analysts Bullish Ignyta Inc (NASDAQ:RXDX) This Week?Wall Street Hints and NewsIgnyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual MeetingBusiness Wire (press release)Ignyta Says RXDX-105 Phase 1 Data to Be Presented (NASDAQ:RXDX)Sonoran Weekly Reviewall 5 news articles »
05/25/16 07:00 PMIgnyta, Inc. (NASDAQ:RXDX) Impact Score At 50 - Investor Newswire - Ignyta, Inc. (NASDAQ:RXDX) Impact Score At 50Investor NewswireAlpha One explored various online articles released on Ignyta, Inc. (NASDAQ:RXDX), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/24/16 03:01 PM4:01 pm Ignyta to present updated data from Phase 1 clinical trial of RXDX-105 at ASCO -
05/24/16 03:00 PMIgnyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced the publication of an abstract for a poster session at the 2016 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
05/23/16 07:06 PMBroker Outlook For The Week Ahead Ignyta, Inc. (RXDX) - Share Trading News - Broker Outlook For The Week Ahead Ignyta, Inc. (RXDX)Share Trading NewsThe most recently updated broker views and price targets issued for Ignyta, Inc. (RXDX) are below. 04/18/2016 – Broker: Jefferies Rating: buy New Target: 20 reiteration. 04/18/2016 – Broker: Piper Jaffray Rating: overweight New Target: 32 reiteration.
05/20/16 07:04 PMRevenue Update on Ignyta Inc(NASDAQ:RXDX) - Trade Calls - Revenue Update on Ignyta Inc(NASDAQ:RXDX)Trade CallsIgnyta Inc(NASDAQ:RXDX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 10, 2016. Earnings per share were $-0.79. Analysts had estimated an EPS of $-0.68. In a different note, On Mar 15, 2016, ...Ignyta, Inc. (RXDX) Updated Broker Price TargetsShare Trading Newsall 2 news articles »
05/17/16 11:20 AMStocks in Focus: Aduro BioTech, Inc. (NASDAQ:ADRO), Ignyta, Inc. (NASDAQ:RXDX), Huntsman Corporation (NYSE ... - KC Register - Stocks in Focus: Aduro BioTech, Inc. (NASDAQ:ADRO), Ignyta, Inc. (NASDAQ:RXDX), Huntsman Corporation (NYSE ...KC RegisterIgnyta, Inc. (NASDAQ:RXDX) announced that it has issued inducement awards to two new non-executive employees. The awards were made on May 15, 2016 under Ignyta's 2015 Employment Inducement Equity Incentive Award Plan, which was adopted ...
05/16/16 12:32 PMIgnyta Inc. (RXDX): Great Point Partners Reports New Stake - Insider Monkey (blog) - Insider Monkey (blog)Ignyta Inc. (RXDX): Great Point Partners Reports New StakeInsider Monkey (blog)In a recent 13G filing with the US SEC, Jeffrey Jay and David Kroin's Great Point Partners reported the acquisition of 2.05 million shares of Ignyta Inc. (NASDAQ:RXDX), which account for 4.94% percent of the total amount of shares, and represent a new ...and more »
05/16/16 09:43 AMIgnyta Inc. (RXDX): Great Point Partners Reports New Stake -
05/12/16 08:19 PMEarnings Expectations Overview: Ignyta Inc (NASDAQ:RXDX) - News Oracle - News OracleEarnings Expectations Overview: Ignyta Inc (NASDAQ:RXDX)News OracleLast Trade: The Company fell -5.93% and finished at $6.19. The daily volume was measured at 345,501.00 shares. The 52-week high of the share price is $19.40 and the 52-week low is $5.07. The company has a market cap of $213.49 million. Its latest ...and more »
05/11/16 08:06 PMIgnyta Inc (RXDX) Stock Price Down 4% on Disappointing Earnings - Washington News Wire - Washington News WireIgnyta Inc (RXDX) Stock Price Down 4% on Disappointing EarningsWashington News WireIgnyta logo Ignyta Inc (NASDAQ:RXDX) fell 4% on Wednesday after the company announced weaker than expected quarterly earnings, MarketBeat.com reports. The stock traded as low as $6.12 and last traded at $6.32, with a volume of 266,899 shares ...Ignyta, Inc. (RXDX) Latest Broker ViewsRisers & FallersAnalysts Offer Insights on Healthcare Companies: Ignyta Inc (NASDAQ: RXDX), Anacor (NASDAQ: ANAC ...Analyst RatingsIgnyta, Inc. (NASDAQ:RXDX): Stock Target from AnalystsNews Tribuneall 8 news articles »
05/10/16 07:49 PMConsensus Rating Review for Ignyta, Inc. (NASDAQ:RXDX) - B.O.D.Y Confidential - Consensus Rating Review for Ignyta, Inc. (NASDAQ:RXDX)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Ignyta, Inc. (NASDAQ:RXDX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/10/16 03:16 PMIgnyta reports 1Q loss -
05/10/16 03:00 PMIgnyta Announces First Quarter 2016 Company Highlights and Financial Results - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2016.
05/10/16 06:07 AMQ1 2016 Ignyta Inc Earnings Release - After Market Close -
05/08/16 09:37 PMIgnyta, Inc. (NASDAQ:RXDX) Basic Consolidated EPS At $-3.443 - RealistInvestor.com - Ignyta, Inc. (NASDAQ:RXDX) Basic Consolidated EPS At $-3.443RealistInvestor.comThe basic EPS generating from continuing operations as announced by Ignyta, Inc. (NASDAQ:RXDX) for the period ended 2015-12-31 was $-3.443. For the quarter ended 2015-12-31, this number was $-3.443. For any specified firm's shares there are multiple ...
05/05/16 08:42 PMEarnings Outlook on Ignyta, Inc. (NASDAQ:RXDX) - B.O.D.Y Confidential - Earnings Outlook on Ignyta, Inc. (NASDAQ:RXDX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Ignyta, Inc. (NASDAQ:RXDX)'s next earnings release which is expected to be posted on or around 2016-05-10. Sell-side research firms on Wall Street are expecting that the company will post EPS of $-0.72 for ...and more »
05/05/16 08:42 PMThursday 5/5 Insider Buying Report: RXDX, ISIL - Casdin bought 232,000 shares of RXDX, for a cost of $6.25 each ... 05/02 IGNYTA: Announces Full Exercise of Underwriters’ Option to Purchase Addit.. 04/30 IGNYTA, INC.: Other Events, Financial Statements and Exhibits (form 8-K) 04/29 IGNYTA: Announces ...
05/04/16 03:00 PMIgnyta to Report 2016 First Quarter Company Highlights and Financial Results and Host Conference Call on May 10, 2016 - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced that it will release its first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016.
05/03/16 07:26 PMAverage Analyst Rating for Ignyta, Inc. (NASDAQ:RXDX) - B.O.D.Y Confidential - Average Analyst Rating for Ignyta, Inc. (NASDAQ:RXDX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Ignyta, Inc. (NASDAQ:RXDX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 09:26 PMStocks To Watch: Ignyta, Inc. (RXDX), La Quinta Holdings Inc. (LQ), Opus Bank (OPB) - iStreetWire - Stocks To Watch: Ignyta, Inc. (RXDX), La Quinta Holdings Inc. (LQ), Opus Bank (OPB)iStreetWireIgnyta, Inc. (RXDX) traded within a range of $6.35 to $7.13 after opening the day at $6.43. The company has seen its stock decrease in value by -48.36% so far this year. The stock was up close to 1.91% on light volume in last trading session and closed ...
05/02/16 09:26 PMTrading the News: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Ignyta, Inc. (NASDAQ:RXDX) - Street Register - Street RegisterTrading the News: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Ignyta, Inc. (NASDAQ:RXDX)Street RegisterAlder Biopharmaceuticals Inc. (NASDAQ:ALDR) lost -3.73% by the end of recent close at $26.55. For the ongoing quarter, the 5 Wall Street analysts providing adjusted earnings per share outlook have a consensus estimate of $-$0.76/share, which would ...and more »
04/29/16 05:00 AMIgnyta Announces Pricing of Public Offering of Common Stock - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced the pricing of an underwritten public offering of 8.0 million shares of its common stock at a price to the public of $6.25 per share.
04/20/16 05:20 AMIGNYTA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
04/17/16 04:17 PMLoxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study -
04/15/16 04:19 PMIgnyta Reports Granting of Inducement Awards - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, announced today that it has issued inducement awards to seven new non-executive employees.
04/08/16 03:28 PMIGNYTA, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement -
04/07/16 03:00 PMIgnyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced the acceptance of an abstract for an oral plenary session presentation relating to its Phase 1 clinical development program for entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, at the 2016 Annual Meeting of the ...
About Ignyta

Ignyta logoIgnyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RXDX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.25
  • 50 Day Moving Average: $6.03
  • 200 Day Moving Average: $8.01
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $218.22M
  • Current Quarter EPS Consensus Estimate: $-2.72 EPS
Additional Links:
Ignyta (NASDAQ:RXDX) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha